Published in Proc Natl Acad Sci U S A on August 23, 2010
EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion. J Cell Biol (2013) 1.06
Actin-associated protein palladin promotes tumor cell invasion by linking extracellular matrix degradation to cell cytoskeleton. Mol Biol Cell (2014) 0.91
Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res (2012) 0.90
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis (2013) 0.89
Gene expression of the lysophosphatidic acid receptor 1 is a target of transforming growth factor beta. Oncogene (2012) 0.81
Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? Curr Pharm Des (2014) 0.80
TIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and Protects Tumor Cells from Apoptosis. PLoS One (2015) 0.78
Membrane-Type 1 Matrix Metalloproteinase Downregulates Fibroblast Growth Factor-2 Binding to the Cell Surface and Intracellular Signaling. J Cell Physiol (2015) 0.77
EphA2 bears plasticity to tumor invasion. Cell Cycle (2013) 0.75
The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy. Cancer Res Treat (2015) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol (2007) 10.17
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
Plasticity of cell migration: a multiscale tuning model. J Cell Biol (2009) 5.82
EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev (2009) 5.61
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol (2009) 4.04
Illuminating the metastatic process. Nat Rev Cancer (2007) 3.80
Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol (2000) 3.53
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Navigating ECM barriers at the invasive front: the cancer cell-stroma interface. Annu Rev Cell Dev Biol (2009) 2.00
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet (2004) 1.92
Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci U S A (2001) 1.83
Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol (2001) 1.71
Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer (1993) 1.63
Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell (2008) 1.58
Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene (2003) 1.52
Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem (2007) 1.50
ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol (2002) 1.48
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46
MT1-MMP: a tethered collagenase. J Cell Physiol (2004) 1.45
Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci U S A (2003) 1.44
TGF-beta3-induced palatogenesis requires matrix metalloproteinases. Mol Biol Cell (2001) 1.42
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem (2008) 1.41
Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol (2005) 1.38
Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain. J Biol Chem (2000) 1.36
Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem (1996) 1.35
MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci (1996) 1.32
The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis. J Biol Chem (1997) 1.28
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26
Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest (2002) 1.21
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer (2004) 1.20
Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem (1999) 1.15
A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res (2010) 1.09
Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res (1996) 1.03
Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem (2000) 1.02
The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol (2006) 1.00
PX-RICS mediates ER-to-Golgi transport of the N-cadherin/beta-catenin complex. Genes Dev (2008) 0.98
Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis (2008) 0.96
FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal (2005) 0.95
Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res (2009) 0.89
Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus. Eur J Hum Genet (1996) 0.88
Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor. Kidney Int (1998) 0.83
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol (2003) 12.96
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev (2002) 8.56
Copy number variation and selection during reprogramming to pluripotency. Nature (2011) 8.24
Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol (2007) 7.75
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol (2003) 7.42
Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A (2002) 6.55
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. Cell (2006) 6.49
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Lymphangiogenesis: Molecular mechanisms and future promise. Cell (2010) 5.84
Hedgehog: functions and mechanisms. Genes Dev (2008) 5.69
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 5.15
DNA-binding specificities of human transcription factors. Cell (2013) 5.14
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J (2010) 4.78
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 4.66
Genomic instability in laminopathy-based premature aging. Nat Med (2005) 4.54
Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods (2011) 4.18
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest (2005) 4.09
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med (2009) 4.07
Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J (2002) 3.99
Lymphangiogenesis and cancer metastasis. Nat Rev Cancer (2002) 3.90
Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet (2002) 3.78
Identification of pathways regulating cell size and cell-cycle progression by RNAi. Nature (2006) 3.60
Multiplexed massively parallel SELEX for characterization of human transcription factor binding specificities. Genome Res (2010) 3.46
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 3.44
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet (2004) 3.38
Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med (2004) 3.32
Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature (2005) 3.31
PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev (2005) 3.29
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol (2009) 3.28
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27
The biology of vascular endothelial growth factors. Cardiovasc Res (2005) 3.22
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science (2011) 3.17
Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol (2002) 2.99
Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell (2013) 2.98
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood (2004) 2.95
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol (2008) 2.85
Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development (2002) 2.68
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood (2006) 2.66
Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science (2012) 2.58
VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood (2002) 2.52
Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol (2008) 2.49
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature (2011) 2.47
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med (2011) 2.38
Signaling and functions of angiopoietin-1 in vascular protection. Circ Res (2006) 2.34
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A (2002) 2.30
Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood (2009) 2.30
A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet (2003) 2.29
Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med (2007) 2.29
VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res (2003) 2.25
FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol (2009) 2.17
Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res (2008) 2.15
Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol (2004) 2.13
Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev (2002) 2.13
Divergence of hedgehog signal transduction mechanism between Drosophila and mammals. Dev Cell (2006) 2.12
Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci (2004) 2.11
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol (2011) 2.09
Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood (2010) 2.04
Hedgehog signal transduction via Smoothened association with a cytoplasmic complex scaffolded by the atypical kinesin, Costal-2. Mol Cell (2003) 2.02
Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev (2005) 2.01
Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest (2013) 1.92
The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol (2005) 1.91
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88
Biological basis of therapeutic lymphangiogenesis. Circulation (2011) 1.85
Vascular growth factors and lymphangiogenesis. Physiol Rev (2002) 1.85
Gene transfer as a tool to induce therapeutic vascular growth. Nat Med (2003) 1.85
Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell (2008) 1.82
Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci (2002) 1.82
Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood (2011) 1.82
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer (2002) 1.80
Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J (2006) 1.79
Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A (2003) 1.79
Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched. Cell (2002) 1.77
Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood (2005) 1.75
Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res (2004) 1.74
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res (2005) 1.73
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res (2007) 1.73
CKIα ablation highlights a critical role for p53 in invasiveness control. Nature (2011) 1.72
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.72
Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol (2010) 1.72
Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood (2005) 1.71
Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med (2010) 1.69
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell (2012) 1.69
Large-scale identification of genes implicated in kidney glomerulus development and function. EMBO J (2006) 1.69
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation (2003) 1.67
Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J (2002) 1.67
MT1-MMP inactivates ADAM9 to regulate FGFR2 signaling and calvarial osteogenesis. Dev Cell (2012) 1.65